A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Public ClinicalTrials.gov record NCT01059630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued obinutuzumab treatment (maintenance monotherapy) compared with bendamustine alone treatment in participants with rituximab-refractory indolent Non-Hodgkin's lymphoma (iNHL). The end of study was defined to when safety follow-up for all patients had been completed (2 years' safety follow-up from last dose).
Study identification
- NCT ID
- NCT01059630
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010 (Actual)
- Primary completion
- Sep 30, 2014 (Actual)
- Completion
- Nov 30, 2018 (Actual)
- Last update posted
- Jan 13, 2020
2010 – 2018
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Mobile | Alabama | 36608 | — |
| Dr. Donald W. Hill, MD, FACP | Casa Grande | Arizona | 85122 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Kaiser Permanente - Bellflower | Bellflower | California | 90706 | — |
| Bay Area Cancer Research Group, LLC | Pleasant Hill | California | 94523 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Washington DC VA Med Center; Hematology | Washington D.C. | District of Columbia | 20422 | — |
| University of Florida | Gainesville | Florida | 32607 | — |
| University of Florida; Division of Hematology/Oncology | Gainesville | Florida | 33610-0277 | — |
| Md Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Rush Cancer Institute | Chicago | Illinois | 60612 | — |
| Quincy Medical Group | Quincy | Illinois | 62301 | — |
| Simmons Cancer Institute | Springfield | Illinois | 62794-9677 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Univ Louisville School of Med | Louisville | Kentucky | 40202 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Meritus Center for Clinical Research | Hagerstown | Maryland | 21740 | — |
| Capitol Comprehensive CA Care | Jefferson City | Missouri | 65101 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Hematology Oncology Assoc SJ | Mount Holly | New Jersey | 08060 | — |
| San Juan Oncology | Farmington | New Mexico | 87401 | — |
| The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc. | Columbus | Ohio | 43219 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97210 | — |
| Pacific Oncology, PC | Portland | Oregon | 97210 | — |
| OHSU Ctr for Health & Healing | Portland | Oregon | 97239 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Sanford Health System | Sioux Falls | South Dakota | 57105 | — |
| South Texas Inst of Cancer | Corpus Christi | Texas | 78405 | — |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Univ of Wisconsin Hosp & Clin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01059630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2020 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01059630 live on ClinicalTrials.gov.